A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Summary

Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

Timeline

Start

2008-06

Primary completion

2008-12

Completion

2008-12

Outcome

Met primary endpoint

registry analysis (superiority or other test); AD Subjects vs MCI Subjects; p = 0.0002; Fisher Exact NCT00702143 ↗

registry analysis (superiority or other test); AD Subjects vs Healthy Controls; p <0.0001; Fisher Exact NCT00702143 ↗

registry analysis (superiority or other test); AD Subjects vs MCI Subjects vs Healthy Controls; p <0.0001; ANOVA NCT00702143 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	florbetapir F 18	Diagnostic / imaging agent	370 mbq	Intravenous

Indications